Insulin glulisine: preclinical hallmarks and clinical efficacy. Issue 2 (March 2009)

• Record Type: Journal Article
• Authors: Schliess, Freimut; Heise, Tim
• Is Part Of: Therapy. Volume 6:Issue 2(2008)
• Page Start: 209
• Page End: 229
• Publication Date: 2009-03
• Subjects: ββ-cells -- euglycemic clamp -- insulin analogues -- insulin-like growth factor -- proliferation -- obesity -- systems biology -- zinc; Therapeutics -- Periodicals; Chemotherapy -- Periodicals; 615.505
• DOI: 10.2217/14750708.6.2.209
• Languages: English
• ISSNs: 1475-0708

Abstract

Insulin glulisine (glulisine) is a new fast-acting human insulin analogue approved for treatment of diabetes Type 1 and 2. Preclinical investigations indicate mitogenic and metabolic potency similar to human insulin, but distinct ββ-cell protective properties, possibly related to a preferential effect on the insulin receptor substrate-2. Clinical trials with regular human insulin as a comparator consistently revealed superiority of glulisine with regard to glycemic control, which brought post-prandial glucose excursions closer to physiological levels without increasing the risk of hypoglycemia. Experimental trials showed specific advantages of glulisine in the treatment of obese and pediatric patients, which requires further evalulation. Certainly, glulisine represents a valuable tool for optimizing glycemic control, and thereby for attenuating micro- and macro-vascular complications.